Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

159.64
+2.701.72%
Post-market: 159.640.00000.00%16:10 EDT
Volume:2.92M
Turnover:465.35M
Market Cap:247.60B
PE:23.90
High:160.30
Open:157.68
Low:157.23
Close:156.94
52wk High:212.71
52wk Low:145.79
Shares:1.55B
Float Shares:1.50B
Volume Ratio:0.82
T/O Rate:0.19%
Dividend:3.17
Dividend Rate:1.99%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.02%
PB:4.92
PE(LYR):24.41

Loading ...

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

TIPRANKS
·
Aug 27

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live
·
Aug 27

AstraZeneca's Tezspire Meets Esophagitis Late-Stage Trial Goals

Dow Jones
·
Aug 27

AstraZeneca Slides Wednesday, Underperforms Market

Dow Jones
·
Aug 27

AstraZeneca Deepens Its Type 2 Diabetes Pipeline With New Global Patient Mapping Study

TIPRANKS
·
Aug 26

AstraZeneca Climbs Tuesday, Outperforms Market

Dow Jones
·
Aug 26

AstraZeneca (AZN) Receives a Sell from Deutsche Bank

TIPRANKS
·
Aug 25

Astrazeneca Prices $2.97 Billion Eurobond Offering

MT Newswires Live
·
Aug 25

AstraZeneca’s AZD4144 Interaction Study Adds Quiet Support to AZN’s Pipeline Story

TIPRANKS
·
Aug 25

AstraZeneca PLC Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 25

AstraZeneca Rallies Friday, Outperforms Market

Dow Jones
·
Aug 22

AstraZeneca’s SELENE 3 Trial Targets Extra Weight-Loss Upside for AZN Investors

TIPRANKS
·
Aug 21

AstraZeneca PLC Stock Rises Thursday, Outperforms Market

Dow Jones
·
Aug 21

Dizhe Pharma Surpasses 500 Million Yuan in First-Half Revenue, Seals Global Exclusive Licensing Pact with AstraZeneca for Sunvozertinib

Deep News
·
Aug 20

Third Indication Approved in China for AstraZeneca's Ultomiris

Stock News
·
Aug 20

Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Aug 20

AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send?

TradingKey
·
Aug 20

Movement Alert|AstraZeneca PLC Rises 3.1% in Regular Trading, Multiple Positive Phase III Lung Cancer Results Coupled with Pharma Sector Strength

Market Focus
·
Aug 19

The Key to Pharma M&A: Never Shopping Hungry - Heard on the Street

Dow Jones
·
Aug 19

UBS Keeps Their Buy Rating on AstraZeneca (AZN)

TIPRANKS
·
Aug 19